Rapamycin, a drug approved for the treatment of cancer and transplant patients increases amyloid-beta protein plaques in the brains of mice.
A molecular process caused by the TREM2 gene mutation in the brain's microglia increases the risk of Alzheimer's disease, a new study reports.
A drug currently being tested in cancer clinical trials appears to prevent dysfunction in an immune cell signaling pathway associated with Alzheimer's disease. Blocking the pathway could prevent Alzheimer's from developing and slow the progression of symptoms for those who already have the disease.
Testing for specific inflammatory proteins in cerebrospinal fluid can help doctors to diagnose the early onset of Alzheimer's disease and track the progression of the disease in patients.
A two-week course of CBD helps normalize and restore the function of two proteins associated with reducing amyloid-beta accumulation in mouse models of familial Alzheimer's disease. CBD also reduces levels of IL-6, an immune protein associated with inflammation in Alzheimer's patients.
DHA treatment reduced the size of the damaged brain area and initiated a repair mechanism in animal models of stroke. DHA affected the levels of MANF and TREM2, two proteins critical for communication between brain cells.